Zealand Pharma sends rescue pen on the market in late June

Zealand Pharma plans to take its approved rescue pen Zegalogue for hypoglycemia to the US market in summer.

Photo: Zealand Pharma / PR

Danish pharmaceutical company Zealand Pharma plans to launch the company's emergency pen Zegalogue on the US market in late June.

The firm announced this at a Tuesday press conference following the US Food and Drug Administration's (FDA) Monday approval of Zegalogue for treating severe incidents of low blood sugar, sometimes referred to as hypoglycemia.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs